Triplet Therapeutics
Pei brings over 20 years of experience in drug discovery and development in the biotechnology and pharmaceutical industries to her role as Head of Pharmacology at Triplet Therapeutics, Inc. Prior to joining the company, she was Senior Principal Investigator and Leader of Visceral Pain Research at Ironwood Pharmaceuticals, where she led translational programs that considerably broadened the path for Linzess® and related guanylate cyclase-C agonist peptides of this class as novel drugs for the treatment of chronic pelvic pain syndromes. Prior to her role at Ironwood Pharmaceuticals, she was a senior scientist at Alnylam Pharmaceuticals, where she led the Huntington’s disease program and several other CNS siRNA delivery and therapeutic programs. Pei received her Ed.M. from Harvard University and her B.S. from Stonehill College.
This person is not in any offices
Triplet Therapeutics
Triplet Therapeutics is a biotechnology company developing transformational treatments for patients with repeat expansion disorders (REDs) -- a group of more than 50 known genetic diseases including Huntington’s disease, myotonic dystrophy, spinocerebellar ataxias, fragile X syndrome, and familial amyotrophic lateral sclerosis (ALS) -- leveraging insights from patient genetics. Triplet designs and develops potential therapeutics for REDs using its proprietary thRED Engine, which enables the Company to develop a single oligonucleotide targeting the DNA Damage Response (DDR) pathway to potentially treat multiple REDs. Triplet is backed by investments from Atlas Venture, MPM Capital and Pfizer Ventures, along with Invus, Partners Innovation Fund and Alexandria Venture Investments.